Whereas 20% of the pituitary adenomas in patients with MEN1 are classified as prolactinomas (1), this type of tumor has not been reported in patients with MEN4, possibly indicating differential effects of CDKN1B and MEN1 mutations on development of lactotropic tumors in the pituitary gland. Here, CDKN1B is linked to neoplasm.